Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
TransMedics Group Inc Market Cap
The TransMedics Group Inc (TMDX) share price is expected to increase by 78.29% over the next year. This is based on calculating the average 12-month share price estimate provided by 10 stock analysts who have covered TMDX. Price targets range from $80 at the low end to $179 at the high end. The current analyst consensus for TMDX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 10 Wall Street analysts have assigned TMDX 8 buy ratings, 2 hold ratings, and 0 sell ratings. This means that analysts expect TransMedics Group Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on TMDX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of TMDX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Suraj Kalia Oppenheimer | Outperform | $125 | Maintains | Dec 3, 2024 |
| Mike Matson Needham | Hold | Reiterates | Dec 3, 2024 | |
| Mike Matson Needham | Hold | $109 | Downgrade | Nov 22, 2024 |
| Matt O'Brien Piper Sandler | Overweight | $110 | Maintains | Nov 20, 2024 |
| William Plovanic Canaccord Genuity | Buy | $104 | Maintains | Nov 20, 2024 |
| Joshua Jennings TD Cowen | Buy | $120 | Maintains | Nov 18, 2024 |
| Allen Gong JP Morgan | Overweight | $116 | Maintains | Oct 29, 2024 |
| Mike Matson Needham | Buy | $109 | Maintains | Oct 29, 2024 |
| Jason Mills Canaccord Genuity | Buy | $109 | Maintains | Oct 29, 2024 |
| Joe Vruwink Baird | Outperform | $150 | Maintains | Oct 29, 2024 |
| Matt O'Brien Piper Sandler | Overweight | $180 | Reiterates | Oct 29, 2024 |
| Suraj Kalia Oppenheimer | Outperform | $125 | Maintains | Oct 29, 2024 |
| Matt O'Brien Piper Sandler | Overweight | $180 | Maintains | Oct 7, 2024 |
| Joe Vruwink Baird | Outperform | $200 | Initiates | Sep 24, 2024 |
| Mike Matson Needham | Buy | $208 | Reiterates | Aug 23, 2024 |
| Mike Matson Needham | Buy | $208 | Initiates | Aug 21, 2024 |
| George Sellers Stephens & Co. | Overweight | $178 | Maintains | Aug 2, 2024 |
| Suraj Kalia Oppenheimer | Outperform | $200 | Maintains | Aug 1, 2024 |
| Jason Mills Canaccord Genuity | Buy | $169 | Maintains | Aug 1, 2024 |
| Matt O'Brien Piper Sandler | Overweight | $180 | Maintains | Aug 1, 2024 |
When did it IPO
2019
Staff Count
584
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Dr. Waleed H. Hassanein M.D.
Market Cap
$2.32B
In 2023, TMDX generated $241.6M in revenue, which was a increase of 158.53% from the previous year. This can be seen as a signal that TMDX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Sun, 08 Dec 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - TransMedics Group (TMDX) saw its stock value more than double from the end of 2023 to late August, marking it as a top-performing stock during that period.
Why It Matters - TransMedics Group's significant stock increase indicates strong market confidence and potential growth, attracting investor interest and suggesting favorable future performance.
Fri, 06 Dec 2024
Sentiment - NEGATIVE
Source - The Motley Fool
Summary - Transmedics Group (TMDX) shares fell over 20% following the announcement of a CFO transition and a reduction in full-year 2024 revenue growth guidance.
Why It Matters - Transmedics' CFO transition and lowered guidance signal potential financial instability and reduced growth prospects, prompting investor concerns and leading to a significant drop in share price.
Tue, 03 Dec 2024
Sentiment - NEUTRAL
Source - The Motley Fool
Summary - TransMedics (TMDX) shares fell 14% as of noon ET on Wednesday, reflecting a decline in the company's stock performance according to S&P Global Market Intelligence.
Why It Matters - TransMedics' significant share drop indicates potential investor concerns over its performance or future prospects, which could affect market sentiment and investment decisions.
Mon, 02 Dec 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - TransMedics Group, Inc. (Nasdaq: TMDX) has appointed a new executive, aiming to enhance its organ transplant therapy solutions for patients with end-stage organ failure.
Why It Matters - Leadership changes can impact a company's strategy and performance. New appointments may signal shifts in direction or focus, influencing investor confidence and stock performance.
Tue, 03 Dec 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Robbins Geller is investigating potential securities law violations by TransMedics Group, Inc. (NASDAQ: TMDX) regarding misleading statements by the company and its executives.
Why It Matters - Investigations into potential securities law violations can lead to stock price volatility, legal liabilities, and loss of investor confidence, impacting TransMedics Group's market performance.
Wed, 04 Dec 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - TransMedics shares fell 60% since August due to a Q3 revenue miss and lowered guidance. Despite near-term challenges, long-term growth is expected, with improved performance anticipated in 2H 2025.
Why It Matters - TransMedics' significant share decline reflects investor disappointment over missed revenue targets and reduced guidance, impacting short-term sentiment despite strong long-term growth potential.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
